

DAFTAR PUSTAKA

- Abdelhafiz, A.H., Wheeldon, N.M., 2004, Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic, *Clinical Therapeutics* 26, 1470–1478. <https://doi.org/10.1016/j.clinthera.2004.09.002>.
- Abraham, N.S., Hlatky, M.A., Antman, E.M., Bhatt, D.L., Bjorkman, D.J., Clark, C.B., Furberg, C.D., Johnson, D.A., Kahi, C J., Laine, L., Mahaffey, K.W., Quigley, E.M., Scheiman, J., Sperling, L.S., Tomaselli, G.F., ACCF/ACG/AHA, 2010, ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents, *Circulation* 122, 2619–2633, <https://doi.org/10.1161/CIR.0b013e318202f701>.
- Agno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M., Palareti, G., 2012, Oral anticoagulant therapy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, *Chest* 141, <https://doi.org/10.1378/chest.11-2292>.
- Al-Omari, A., Alhuqbani, W., Zaidi, A., Al-Subaie, M., AlHindi, A., Abogosh, A., Alrasheed, A.K., Alsharafi, A.A., Alhuqbani, M.N., Salih, S., Alhedaithy, M.A., Abdulqawi, R., Ismail, A.F., Alhumaid, S., Hamdan, N., Saad, F., Olhaye, F.A., Eltahir, T. A., Alomari, M., Alshehery, M., Yassiri, A., Al-Tawfiq, J.A., Al Mutair, A., 2020, Clinical Characteristics Of Non-Intensive Care Unit COVID-19 Patients In Saudi Arabia: A Descriptive Cross-Sectional Study, *J Infect Public Health* 13, 1639-1644, <https://doi.org/10.1016/j.jiph.2020.09.003>.
- Amarya, S., Singh, K., Sabharwal, M., 2015, Changes during aging and their association with malnutrition, *J. Clin. Gerontol* 6, 78–84, <https://doi.org/10.1016/j.jcgg.2015.05.003>.
- Arboix, A., Vall-Lloera, A., García-Eroles, L., Massons, J., Oliveres, M., Targa, C., 2002, Clinical features and functional outcome of intracerebral hemorrhage in patients aged 85 and older, *Journal of the American Geriatrics Society* 50, 449–454, <https://doi.org/10.1046/j.1532-5415.2002.50109.x>.
- Atmaja, K.S., Wicaksana, A.A.G.O.S., Putra, W.A.S., Putra, W.W.S., 2021, Hubungan konsentrasi serum c-reactive protein dan d-dimer dengan derajat keparahan dan mortalitas pasien Covid-19, *Intisari Sains Medis* 12, 680-685, <https://doi.org/10.15562/ism.v12i2.971>.
- Aursulesei, V., Costache, I.I., 2019, Anticoagulation in chronic kidney disease:

- from guidelines to clinical practice, *Clin. Cardiol* 42, 774–782, <https://doi.org/10.1002/clc.23196>.
- Barnes G.D., 2020, Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematology, *American Society of Hematology, Education Program* 2020, 642–648. <https://doi.org/10.1182/hematology.2020000151>.
- Barnes, G.D., Burnett, A., Allen, A., Blumenstein, M., Clark, N.P., Cuker, A., Dager, W.E., Deitelzweig, S.B., Ellsworth, S., Garcia, D., Kaatz, S., Minichiello, T., 2020, Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum, *J. Thromb. Thrombolysis*, 1–10, <https://doi.org/10.1007/s11239-020-02138-z>.
- Bassetti, M., Vena, A., Giacobbe, D.R., 2020, The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm, *Eur. J. Clin. Invest* 50, e13209, <https://doi.org/10.1111/eci.13209>.
- Berger, J.S., Kunichoff, D., Adhikari, S., Ahuja, T., Amoroso, N., Aphinyanaphongs, Y., Cao, M., Goldenberg, R., Hindenburg, A., Horowitz, J., Parnia, S., Petrilli, C., Reynolds, H., Simon, E., Slater, J., Yaghi, S., Yuriditsky, E., Hochman, J., Horwitz, L.I., 2020, Prevalence and outcomes of d-dimer elevation in hospitalized patients with covid-19, *Arteriosclerosis, Thrombosis, and Vascular Biology* 40, 2539–2547, <https://doi.org/10.1161/ATVBAHA.120.314872>.
- Beyan, E., Beyan, C., Vaizoglu, S.A., 2010, Predisposing preventable factors in patients with bleeding due to warfarin usage: Evaluation of 114 patients, *Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis* 16, 684–687, <https://doi.org/10.1177/1076029609338049>.
- Beyth, R.J., Quinn, L.M., Landefeld, C.S., 1998, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, *Am. J. Med* 105, 91–99, [https://doi.org/10.1016/s0002-9343\(98\)00198-3](https://doi.org/10.1016/s0002-9343(98)00198-3).
- Bikdeli, B., Madhavan, M.V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C.D., Ageno, W., Madjid, M., Guo, Y., Tang, L.V., Hu, Y., Giri, J., Cushman, M., Quéré, I., Dimakakos, E.P., Gibson, C.M., Lippi, G., Favaloro, E.J., Fareed, J., Caprini, J.A., Tafur, A.J., Burton, J.R., Francese, D.P., Wang, E.Y., Falanga, A., McLintock, C., Hunt, B.J., Spyropoulos, A.C., Barnes, G.D., Eikelboom, J.W., Weinberg, I., Schulman, S., Carrier, M., Piazza, G., Beckman, J.A., Steg, P.G., Stone, G.W., Rosenkranz, S., Goldhaber, S.Z., Parikh, S.A., Monreal, M., Krumholz, H.M., Konstantinides, S.V., Weitz, J.I., Lip, G.Y.H., Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function, 2020, COVID-19

- and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review, *J. Am. Coll. Cardiol* 75, 2950–2973, <https://doi.org/10.1016/j.jacc.2020.04.031>.
- Bogoch, I.I., Watts, A., Thomas-Bachli, A., Huber, C., Kraemer, M.U.G., Khan, K., 2020, Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel, *J. Travel Med* 27, taaa008, <https://doi.org/10.1093/jtm/taaa008>.
- Brunner, Suddarth, 2013, *Keperawatan Medikal Bedah*, EGC, Jakarta.
- Burhan, E., Fathiyah, I., Agus, D.S., Tjandra, Y.A., Teguh, R.S., Yani, J.S., Rezki, T., Bintang, Y.M.S., Diah, H., Heidy, A., 2020, *Pneumonia Covid-19 Diagnosis dan Penatalaksanaan di Indonesia*, PDPI, Jakarta.
- Capodanno, D., Angiolillo, D.J., 2012, Antithrombotic therapy in patients with chronic kidney disease, *Circulation* 125, 2649–2661, <https://doi.org/10.1161/CIRCULATIONAHA.111.084996>.
- Chandra, A., Chakraborty, U., Ghosh, S., Dasgupta, S., 2022, Anticoagulation in COVID-19: current concepts and controversies, *Postgraduate Medical Journal* 98, 395–402. <https://doi.org/10.1136/postgradmedj-2021-139923>.
- Chisholm-Burns, M.A., Terry, L.S., Barbara, G.W., Patrick, M.M., Jill, M.K., DiPiro, J.T., 2016, *Pharmacotherapy Principles and Practice*, 4th ed. McGraw-Hill Education/Medical, New York.
- Chesebro, J. H., Knatterud, G., Roberts, R., Borer, J., Cohen, L. S., Dalen, J., Dodge, H. T., Francis, C. K., Hillis, D., Ludbrook, P., 1987, Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. *Circulation* 76, 142–154, <https://doi.org/10.1161/01.cir.76.1.142>.
- Connors, J.M., Levy, J.H., 2020, COVID-19 and its implications for thrombosis and anticoagulation. *Blood* 135, 2033–2040, <https://doi.org/10.1182/blood.2020006000>.
- Cuker, A., Tseng, E.K., Nieuwlaat, R., Angchaisuksiri, P., Blair, C., Dane, K., Davila, J., DeSancho, M.T., Diuguid, D., Griffin, D.O., Kahn, S.R., Klok, F.A., Lee, A.I., Neumann, I., Pai, A., Pai, M., Righini, M., Sanfilippo, K. M., Siegal, D., Skara, M., ... Schünemann, H. J, 2021, American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19, *Blood Advances* 5, 872–888, <https://doi.org/10.1182/bloodadvances.2020003763>.
- De Caterina, R., Andersson, U., Alexander, J.H., Al-Khatib, S.M., Bahit, M.C., Goto, S., Hanna, M., Held, C., Hohnloser, S., Hylek, E.M., Lanus, F., Lopes, R.D., López-Sendón, J., Renda, G., Horowitz, J., Granger, C.B., Wallentin, L., 2016, History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial

- Fibrillation trial, *Am. Heart J* 175, 175–183, <https://doi.org/10.1016/j.ahj.2016.01.005>.
- de Wit, E., van Doremalen, N., Falzarano, D., Munster, V.J., 2016, SARS and MERS: recent insights into emerging coronaviruses, *Nat. Rev. Microbiol* 14, 523–534, <https://doi.org/10.1038/nrmicro.2016.81>.
- Decousus, H., Tapson, V.F., Bergmann, J.-F., Chong, B.H., Froehlich, J.B., Kakkar, A.K., Merli, G.J., Monreal, M., Nakamura, M., Pavanello, R., Pini, M., Piovela, F., Spencer, F.A., Spyropoulos, A.C., Turpie, A.G.G., Zotz, R.B., FitzGerald, G., Anderson, F.A., 2011, Factors at Admission Associated With Bleeding Risk in Medical Patients: Findings From the IMPROVE Investigators, *CHEST* 139, 69–79, <https://doi.org/10.1378/chest.09-308>.
- Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., Smith, L., 2020, Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review, *Int. J. Environ. Res. Public Health* 17, E2690, <https://doi.org/10.3390/ijerph17082690>.
- Ding, W.Y., Harrison, S., Gupta, D., Lip, G., Lane, D.A., 2020, Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies, *Frontiers in Medicine* 7, 54, <https://doi.org/10.3389/fmed.2020.00054>.
- Fang, M.C., Go, A.S., Hylek, E.M., Chang, Y., Henault, L.E., Jensvold, N.G., Singer, D.E., 2006, Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study, *J. Am. Geriatr. Soc* 54, 1231–1236, <https://doi.org/10.1111/j.1532-5415.2006.00828.x>.
- Farkouh, M.E., Stone, G.W., Lala, A., Bagiella, E., Moreno, P.R., Nadkarni, G.N., Ben-Yehuda, O., Granada, J.F., Dressler, O., Tinuoye, E.O., Granada, C., Bustamante, J., Peyra, C., Godoy, L.C., Palacios, I.F., Fuster, V., 2022, Anticoagulation in patients with covid-19: jacc review topic of the week, *Journal of the American College of Cardiology* 79, 917–928, <https://doi.org/10.1016/j.jacc.2021.12.023>.
- Fehr, A.R., Perlman, S., 2015, Coronaviruses: An Overview of Their Replication and Pathogenesis, *Coronaviruses* 1282, 1–23, https://doi.org/10.1007/978-1-4939-2438-7_1.
- Flores, B., Trivedi, H.D., Robson, S.C., Bonder, A., 2017, Hemostasis, bleeding and thrombosis in liver disease, *Journal Of Translational Science* 3, 3, <https://doi.org/10.15761/JTS.1000182>.
- Forman, D.E., and Goyette, R.E., 2014, Oral anticoagulation therapy for elderly patients with atrial fibrillation: utility of bleeding risk covariates to better understand and moderate risks, *Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis* 20, 1, 5–15, <https://doi.org/10.1177/1076029613492010>.

- Fu, L., Zhang, F., Li, G., Onishi, A., Bhaskar, U., Sun, P., Linhardt, R.J., 2014, Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration, *Journal of Pharmaceutical Sciences* 103, 1375–1383. <https://doi.org/10.1002/jps.23939>.
- Fukaya, H., Ako, J., 2018, Is Female Sex Always a Risk for Bleeding? *Circ. J* 82, 1743–1745, <https://doi.org/10.1253/circj.CJ-18-0402>.
- Gabarre, P., Dumas, G., Dupont, T., Darmin, M., Azoulay, E., Zafrani, L., 2020, Acute kidney injury in critically ill patients with COVID-19, *Intensive Care Med* 46, 1339–1348, <https://doi.org/10.1007/s00134-020-06153-9>.
- Garcia, D.A., Baglin, T.P., Weitz, J.I., Samama, M.M., 2012, Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, *Chest* 141, e24S–e43S, <https://doi.org/10.1378/chest.11-2291>.
- Gómez-Mesa, J.E., Galindo-Coral, S., Montes, M.C., Muñoz Martin, A.J., 2021, Thrombosis and Coagulopathy in COVID-19, *Current Problems in Cardiology* 46, 100742. <https://doi.org/10.1016/j.cpcardiol.2020.100742>
- Gorbalenya, A., Baker, S., Baric, R., de Groot, R., Drosten, C., Gulyaeva, A., Haagmans, B., Lauber, C., Leontovich, A., Neuman, B., Penzar, D., Perlman, S., Poon, L., Samborskiy, D., Sidorov, I., Sola, I., Ziebuhr, J., 2020, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, *Nat. Microbiol* 5, <https://doi.org/10.1038/s41564-020-0695-z>.
- Graipe, A., Ulvenstam, A., Irevall, A.L., Söderström, L., Mooe, T., 2021, Incidence and predictors of serious bleeding during long-term follow-up after acute coronary syndrome in a population-based cohort study, *Sci Rep* 11, 21967, <https://doi.org/10.1038/s41598-021-01525-7>.
- Grimnes, G., Isaksen, T., Tichelaar, Y., Brox, J., Brækkan, S.K., Hansen, J.B., 2018, C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study, *Haematologica* 103, 1245–1250, <https://doi.org/10.3324/haematol.2017.186957>.
- Halaby, R., Cuker, A., Yui, J., Matthews, A., Ishaaya, E., Traxler, E., Domenico, C., Cooper, T., Tierney, A., Niami, P., van der Rijst, N., Adusumalli, S., Gutsche, J., Giri, J., Pugliese, S., Hecht, T., Pishko, A.M., 2021, Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study, *Journal of Thrombosis and Haemostasis : JTH* 19, 1533–1545, <https://doi.org/10.1111/jth.15310>.
- Hamanaka, Y., Sotomi, Y., Hirata, A., Kobayashi, T., Ichibori, Y., Makino, N., Hayashi, T., Sakata, Y., Hirayama, A., Higuchi, Y., 2020, Persistent Systemic Inflammation Is Associated With Bleeding Risk in Atrial Fibrillation Patients, *Circulation Journal : Official Journal of The Japanese Circulation Society* 84, 411–418, <https://doi.org/10.1253/circj.CJ-19-1006>.

- Harter, K., Levine, M., Henderson, S.O., 2015, Anticoagulation drug therapy: a review. *West, J. Emerg. Med* 16, 11–17, <https://doi.org/10.5811/westjem.2014.12.22933>.
- Henry, B.M., Vikse, J., Benoit, S., Favaloro, E.J., Lippi, G., 2020, Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis, *Clin. Chim. Acta Int. J. Clin. Chem* 507, 167, <https://doi.org/10.1016/j.cca.2020.04.027>.
- Holbrook, A., Schulman, S., Witt, D.M., Vandvik, P.O., Fish, J., Kovacs, M.J., Svensson, P.J., Veenstra, D.L., Crowther, M., Guyatt, G.H., 2012, Evidence-Based Management of Anticoagulant Therapy, *Chest* 141, e152S–e184S, <https://doi.org/10.1378/chest.11-2295>.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., Cao, B., 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, *Lancet Lond. Engl* 395, 497–506, [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- Hughes, M., Lip, G.Y.H., Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care, 2007, Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review, *QJM Mon. J. Assoc. Physicians* 100, 599–607, <https://doi.org/10.1093/qjmed/hcm076>.
- Hughes, S., Szeki, I., Nash, M.J., Thachil, J., 2014, Anticoagulation in chronic kidney disease patients—the practical aspects, *Clin. Kidney J* 7, 442–449, <https://doi.org/10.1093/ckj/sfu080>.
- Jamini, T., 2021, Gambaran Lama Hari Rawat Inap Pasien Covid-19 Berdasarkan Karakteristik Demografi, Klinis, dan Hasil Laboratorium Pasien di Ruang Perawatan Covid-19 RSUD H. Boejasin Pelaihari Tahun 2021, *Jurnal Penelitian UPR: Kaharati* 1, 1–9, <https://doi.org/10.52850/jptupr.v1i2.4086>.
- Joly, B.S., Siguret, V., Veyradier, A., 2020, Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19, *Intensive Care Med* 46, 1603–1606, <https://doi.org/10.1007/s00134-020-06088-1>.
- Jun, M., James, M. T., Manns, B. J., Quinn, R. R., Ravani, P., Tonelli, M., Perkovic, V., Winkelmayer, W. C., Ma, Z., Hemmelgarn, B. R., Alberta Kidney Disease Network, 2015, The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study, *BMJ (Clinical research ed.)* 350, h246, <https://doi.org/10.1136/bmj.h246>.
- Katsoularis, I., Fonseca-Rodríguez, O., Farrington, P., Jerndal, H., Lundevaller,

- E.H., Sund, M., Lindmark, K., Connolly, A.F., 2022, Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study, *British Medical Journal* 377, e069590, <https://doi.org/10.1136/bmj-2021-069590>.
- Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z., Nelson, M.E., Wells, P.S., Gould, M.K., Dentali, F., Crowther, M., Kahn, S.R., 2012, Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, *Chest* 141, e419S-e496S, <https://doi.org/10.1378/chest.11-2301>.
- Kemenkes RI, 2020, *Pedoman Pendegahan dan Pengendalian Coronavirus Disease (Covid-19)*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kemenkes RI, 2021, *Manajemen Klinis Tata Laksana Corona Virus Disease 2019 (Covid-19) Di Fasilitas Pelayanan Kesehatan*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kemenkes RI., 2022. *Situasi Virus Corona*, <https://data.covid19.go.id/public/index.html>, 21 Maret 2022.
- Kent, A.P., Brueckmann, M., Fraessdorf, M., Connolly, S.J., Yusuf, S., Eikelboom, J.W., Oldgren, J., Reilly, P.A., Wallentin, L., Ezekowitz, M.D., 2018, Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation, *Journal of the American College of Cardiology* 72, 255–267. <https://doi.org/10.1016/j.jacc.2018.04.063>.
- Klok, F.A., Judith, K., Menno, V.H., Stavros, K., Mareike, L., Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review, 2015, *Eur Respir J* 45, 201-210, <https://doi.org/10.1183/09031936.00040714>.
- Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D. a. M.P.J., Kant, K.M., Kaptein, F.H.J., van Paassen, J., Stals, M. a. M., Huisman, M.V., Endeman, H., 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, *Thromb. Res* 191, 145–147, <https://doi.org/10.1016/j.thromres.2020.04.013>.
- Kollias, A., Kyriakoulis, K.G., Dimakakos, E., Poulakou, G., Stergiou, G.S., Syrigos, K., 2020, Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action, *Br. J. Haematol* 189, 846–847, <https://doi.org/10.1111/bjh.16727>.
- Konstantinides, S.V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.J., Harjola, V.-P., Huisman, M.V., Humbert, M., Jennings, C.S., Jiménez, D., Kucher, N., Lang, I.M., Lankeit, M., Lorusso, R., Mazzolai, L., Meneveau, N., Ní Áinle, F., Prandoni, P., Pruszczyk, P., Righini, M., Torbicki, A., Van Belle, E., Zamorano, J.L., ESC Scientific Document Group, 2020, 2019

- ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS), *Eur. Heart J* 41, 543–603, <https://doi.org/10.1093/eurheartj/ehz405>.
- Korsman, S., Gert, V.Z., Wolfgang, P., Louise, N., Monique, A., 2012, *Virology*, 1st ed, Churchill Livingstone, Africa.
- Kubitza, D., Becka, M., Voith, B., Zuehlsdorf, M., Wensing, G., 2005, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor, *Clin. Pharmacol. Ther* 78, 412–421, <https://doi.org/10.1016/j.clpt.2005.06.011>.
- Lamberts, M., Lip, G.Y., Hansen, M.L., Lindhardsen, J., Olesen, J.B., Raunsø, J., Olsen, A.M., Andersen, P.K., Gerds, T.A., Fosbøl, E.L., Torp-Pedersen, C., Gislason, G.H., 2014, Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. *Annals of Internal Medicine* 161, 690–698, <https://doi.org/10.7326/M13-1581>.
- Lassen, M.R., Gallus, A., Raskob, G.E., Pineo, G., Chen, D., Ramirez, L.M., ADVANCE-3 Investigators, 2010, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement, *The New England Journal Of Medicine* 363, 2487–2498, <https://doi.org/10.1056/NEJMoa1006885>.
- Lazrak, H.H., René, E., Elftouh, N., Lafrance, J.P., 2018, Association between low-molecular-weight heparin and risk of bleeding among hemodialysis patients: a retrospective cohort study, *Canadian Journal of Kidney Health and Disease* 5, 2054358118792010. <https://doi.org/10.1177/2054358118792010>
- Levi, M., Thachil, J., Iba, T., Levy, J.H., 2020, Coagulation abnormalities and thrombosis in patients with COVID-19, *Lancet Haematol* 7, e438–e440, [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9).
- Levine, M.N., Raskob, G., Beyth, R.J., Kearon, C., Schulman, S., 2004, Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, *Chest* 126, 287S–310S, https://doi.org/10.1378/chest.126.3_suppl.287S.
- Leykum, L., Pugh, J., Diuguid, D., Papadopoulos, K., 2006, Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient, *Journal of Hospital Medicine* 1, 168–176, <https://doi.org/10.1002/jhm.97>.
- Lieu, C., Shi, J., Donat, F., Van Horn, R., Brian, W., Newton, J., Delbressine, L., Vos, R., 2002, Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs, *Clin. Pharmacokinet* 41, Suppl 2, 19–26, <https://doi.org/10.2165/00003088-200241002-00003>.
- Liu, X., Zhou, H., Zhou, Y., Wu, X., Zhao, Y., Lu, Y., Tan, W., Yuan, M., Ding,

- X., Zou, J., Li, R., Liu, H., Ewing, R. M., Hu, Y., Nie, H., Wang, Y., 2020, Risk factors associated with disease severity and length of hospital stay in COVID-19 patients, *The Journal of Infection* 81, 1, e95–e97. <https://doi.org/10.1016/j.jinf.2020.04.008>.
- Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., Kucher, N., Studt, J.-D., Sacco, C., Bertuzzi, A., Sandri, M.T., Barco, S., Humanitas COVID-19 Task Force, 2020, Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy, *Thromb. Res* 191, 9–14, <https://doi.org/10.1016/j.thromres.2020.04.024>.
- Mant, J., Hobbs, F.D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G.Y., Murray, E., BAFTA investigators, Midland Research Practices Network (MidReC)., 2007, Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet (London, England)* 370, 493–503, [https://doi.org/10.1016/S0140-6736\(07\)61233-1](https://doi.org/10.1016/S0140-6736(07)61233-1).
- Marcucci, R., Cioni, G., Giusti, B., Fatini, C., Rossi, L., Pazzi, M., Abbate, R., 2014, Gender and anti-thrombotic therapy: from biology to clinical implications, *J Cardiovasc. Transl. Res* 7, 72–81, <https://doi.org/10.1007/s12265-013-9534-4>.
- Molnar, A.O., Bota, S.E., Garg, A.X., Harel, Z., Lam, N., McArthur, E., Nesrallah, G., Perl, J., Sood, M.M., 2016, The risk of major hemorrhage with ckd. *Journal of the American Society of Nephrology : JASN* 27, 2825–2832. <https://doi.org/10.1681/ASN.2015050535>.
- Morabia, A., 1986, Heparin doses and major bleedings, *Lancet Lond. Engl* 1, 1278–1279, [https://doi.org/10.1016/s0140-6736\(86\)91421-2](https://doi.org/10.1016/s0140-6736(86)91421-2).
- Muciño-Bermejo, J., Carrillo-Esper, R., Méndez-Sánchez, N., Uribe, M., 2015, Thrombosis and hemorrhage in the critically ill cirrhotic patients: five years retrospective prevalence study, *Annals of Hepatology* 14, 93–98.
- Mueck, W., Becka, M., Kubitz, D., Voith, B., Zuehlendorf, M., 2007, Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects, *Int. J. Clin. Pharmacol. Ther* 45, 335–344, <https://doi.org/10.5414/cpp45335>.
- Musoke, N., Lo, K.B., Albano, J., Peterson, E., Bhargav, R., Gul, F., DeJoy, R., Salacup, G., Pelayo, J., Tipparaju, P., Azmaiparashvili, Z., Patarroyo-Aponte, G., Rangaswami, J., 2020, Anticoagulation and bleeding risk in patients with COVID-19, *Thromb. Res* 196, 227–230, <https://doi.org/10.1016/j.thromres.2020.08.035>.
- Nadkarni, G.N., Lala, A., Bagiella, E., Chang, H.L., Moreno, P.R., Pujadas, E., Arvind, V., Bose, S., Charney, A.W., Chen, M.D., Cordon-Cardo, C., Dunn, A.S., Farkouh, M.E., Glicksberg, B.S., Kia, A., Kohli-Seth, R., Levin, M.A., Timsina, P., Zhao, S., Fayad, Z.A., Fuster, V., 2020,

- Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19, *J. Am. Coll. Cardiol* 76, 1815–1826, <https://doi.org/10.1016/j.jacc.2020.08.041>.
- Neal, M. J., 2016, *Medical Pharmacology At a Glance*, eighth edition, WILEY Blackwell, Singapore.
- Notoatmodjo, S., 2010, *Promosi Kesehatan Teori dan Aplikasi*, Rineka Cipta, Jakarta.
- Oliynyk, O., Barg, W., Slifirczyk, A., Oliynyk, Y., Dubrov, S., Gurianov, V., Rorat, M., 2021, Comparison of the effect of unfractionated heparin and enoxaparin sodium at different doses on the course of covid-19-associated coagulopathy, *Life* (Basel, Switzerland) 11, 1032. <https://doi.org/10.3390/life11101032>.
- Paikin, J. S., Wright, D.S., Eikelboom, J.W., 2011, Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials, *Blood Reviews* 25, 123–129, <https://doi.org/10.1016/j.blre.2011.01.007>.
- Palareti, G., and Cosmi, B., 2009, Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients, *Thrombosis and Haemostasis* 102, 268–278, <https://doi.org/10.1160/TH08-11-0730>.
- Paranjpe, I., Fuster, V., Lala, A., Russak, A.J., Glicksberg, B.S., Levin, M.A., Charney, A.W., Narula, J., Fayad, Z.A., Bagiella, E., Zhao, S., Nadkarni, G.N., 2020, Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. *Journal of the American College of Cardiology* 76, 122–124, <https://doi.org/10.1016/j.jacc.2020.05.001>.
- Passacquale, G., Sharma, P., Perera, D., Ferro, A., 2022, Antiplatelet therapy in cardiovascular disease: Current status and future directions, *British Journal of Clinical Pharmacology* 88, 2686–2699, <https://doi.org/10.1111/bcp.15221>.
- Patel, I., Akoluk, A., Douedi, S., Upadhyaya, V., Mazahir, U., Costanzo, E., Flynn, D., 2020, Life-Threatening Psoas Hematoma due to Retroperitoneal Hemorrhage in a COVID-19 Patient on Enoxaparin Treated With Arterial Embolization: A Case Report, *J. Clin. Med. Res* 12, 458–461, <https://doi.org/10.14740/jocmr.v12i7.4256>.
- Penttilä, T., Mika, L., Jussi, N., Juha, M., Houssem, K., Riitta, L., Pekka, R., Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy, *European Heart Journal - Cardiovascular Pharmacotherapy* 5, 29–36, <https://doi.org/10.1093/ehjcvp/pvy026>.
- Pepitasari, B.D., Truly, D.A., 2021, Gambaran Tatalaksana Pada Pasien Covid-19 Terkonfirmasi di Rumah Sakit X Kota Surakarta Periode Maret-Desember 2020, *Indonesian Journal on Medical Sciences* 8, 119–126.
- Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J., Lip, G. Y.,

- 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, *Chest* 138, 1093–1100, <https://doi.org/10.1378/chest.10-0134>.
- Poudel, A., Poudel, Y., Adhikari, A., Aryal, B.B., Dangol, D., Bajracharya, T., Maharjan, A., Gautam, R., 2021, D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19, *PloS One* 16, e0256744, <https://doi.org/10.1371/journal.pone.0256744>.
- Pratiwi, A.D.E., Dhimas, A., 2021, Gambaran Penggunaan Antikoagulan pada Pasien Covid-19 di Salah Satu Rumah Sakit Rujukan Covid-19 di Kota Semarang, *Sebatik* 25, 442-448, <https://doi.org/10.46984/sebatik.v25i2.1619>.
- Price, S.A., Wilson, L.M., 2014, *Patofisiologi: Konsep Klinis Proses-Proses Penyakit*, EGC, Jakarta.
- Rao, M.P., Halvorsen, S., Wojdyla, D., Thomas, L., Alexander, J.H., Hylek, E.M., Hanna, M., Bahit, M.C., Lopes, R.D., De Caterina, R., Erol, C., Goto, S., Lanus, F., Lewis, B.S., Husted, S., Gersh, B.J., Wallentin, L., Granger, C.B., Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators, 2015, Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial, *J. Am. Heart Assoc* 4, e002015, <https://doi.org/10.1161/JAHA.115.002015>.
- Ren, L.L., Wang, Y.M., Wu, Z.Q., Xiang, Z.C., Guo, L., Xu, T., Jiang, Y.Z., Xiong, Y., Li, Y.J., Li, X.W., Li, H., Fan, G.H., Gu, X.Y., Xiao, Y., Gao, H., Xu, J.Y., Yang, F., Wang, X.M., Wu, C., Chen, L., Liu, Y.W., Liu, B., Yang, J., Wang, X.R., Dong, J., Li, L., Huang, C.L., Zhao, J.P., Hu, Y., Cheng, Z.S., Liu, L.L., Qian, Z.H., Qin, C., Jin, Q., Cao, B., Wang, J.W., 2020, Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study, *Chinese Medical Journal* 133, 1015–1024, <https://doi.org/10.1097/CM9.0000000000000722>.
- Riedel, S., Morse, S., Mietzner, T., Jawetz, Melnick, 2019, *Medical Microbiology*, 28th ed, Mc Graw Hill Education/Medical, New York.
- Rostami, M., Hassan, M., 2020, D-dimer level in COVID-19 infection: a systematic review, *Expert Review of Hematology* 13, 1265–1275, <https://doi.org/10.1080/17474086.2020.1831383>.
- Rydberg, D.M., Linder, M., Malmström, R.E., Andersen, M., 2020, Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication, *Eur J Clin Pharmacol* 76, 867–876, <https://doi.org/10.1007/s00228-020-02856-6>.
- Saryono, Mekar, D.A., 2013, *Metodologi Penelitian Kualitatif dan Kuantitatif*

Dalam Bidang Kesehatan, Nuha Medik, Yogyakarta.

- Schulman, S., Beyth, R.J., 2005, Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation, *Eur. Heart J. Suppl* 7, C34–C40, <https://doi.org/10.1093/eurheartj/sui018>.
- Schulman, S., Kearon, C., and Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *Journal of Thrombosis And Haemostasis: JTH* 3, 692–694. <https://doi.org/10.1111/j.1538-7836.2005.01204.x>.
- Snedecor, G.W., Cochran, W.G., 1967, *Statistical Methods*, 6th Edition, Iowa State University Press, Ames.
- Spyropoulos, A.C., Levy, J.H., Ageno, W., Connors, J.M., Hunt, B.J., Iba, T., Levi, M., Samama, C.M., Thachil, J., Giannis, D., Douketis, J.D., Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasi, 2020, Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19, *Journal of Thrombosis and Haemostasis* 18, 1859-1865, <https://doi.org/10.1111/jth.14929>.
- Subramanya, V., Claxton, J.S., Lutsey, P.L., MacLehose, R.F., Chen, L.Y., Chamberlain, A.M., Norby, F.L., Alonso, A., 2021, Sex differences in treatment strategy and adverse outcomes among patients 75 and older with atrial fibrillation in the MarketScan database, *BMC Cardiovasc Disord* 21, 598, <https://doi.org/10.1186/s12872-021-02419-2>.
- Susilo, A., Rumende, C.M., Pitoyo, C.W., Santoso, W.D., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E.J., Chen, L.K., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C.O.M., Yuniastuti, E., 2020, Coronavirus Disease 2019: Tinjauan Literatur Terkini, *J. Penyakit Dalam Indones* 7, 45–67, <https://doi.org/10.7454/jpdi.v7i1.415>.
- Tacquard, C., Alexandre, M., Alexandre, G., Yves, G., Sophie, S., Anne, G., Pierre, A., 2021, Anticoagulation in COVID-19: not strong for too long?, *Anaesthesia Critical Care & Pain Medicine* 40, 2, <https://doi.org/10.1016/j.accpm.2021.100857>.
- Tang, N., Bai, H., Chen, X., Gong, J., Li, D., Sun, Z., 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, *J. Thromb. Haemost JTH* 18, 1094–1099, <https://doi.org/10.1111/jth.14817>.
- Ten Cate, H., 2021, Surviving Covid-19 with Heparin?, *The New England Journal Of Medicine* 385, 845–846, <https://doi.org/10.1056/NEJMe2111151>.
- Terpos, E., Ntanasis-Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T.N.,

- Politou, M., Psaltopoulou, T., Gerotziafas, G., Dimopoulos, M.A., 2020, Hematological findings and complications of COVID-19, *Am. J. Hematol* 95, 834–847, <https://doi.org/10.1002/ajh.25829>.
- Ti, S., Pa, H., Tf, K., Ef, E., 2004, Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients, *Stroke* 35, <https://doi.org/10.1161/01.STR.0000141933.75462.c2>.
- Trinh, M., Chang, D.R., Govindarajulu, U.S., Kane, E., Fuster, V., Kohli-Seth, R., Ahmd, S., Levin, M.A., Chen, M.D., 2020, Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated COVID-19 patients, *MedRxiv*, <https://doi.org/10.1101/2020.05.30.20117929>.
- Tripodi, A., 2015, Hemostasis abnormalities in cirrhosis, *Current Opinion in Hematology* 22, 406–412, <https://doi.org/10.1097/MOH.0000000000000164>.
- Tufano, A., Guida, A., Di Minno, M.N.D., Prisco, D., Cerbone, A.M., Di Minno, G., 2011, Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. *Semin. Thromb. Hemost* 37, 267–274, <https://doi.org/10.1055/s-0031-1273090>.
- Voves, C., Wuillemin, W.A., Zeerleder, S., 2006, International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients, *Blood Coagul. Fibrinolysis* 17, 445–451, <https://doi.org/10.1097/01.mbc.0000240916.63521.2e>.
- Wang, Z., Ji, J., Liu, Y., Liu, R., Zha, Y., Chang, X., 2020, Survival Analysis Of Hospital Length Of Stay Of Novel Coronavirus (COVID-19) Pneumonia Patients In Sichuan, China, *MedRxiv* 2020, 1-23, <https://doi.org/10.1101/2020.04.07.20057299>.
- Walker, C., Luigi M.B., 2018, Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited, *Postgraduate Medicine* 130, 55–71, <https://doi.org/10.1080/00325481.2018.1412799>.
- Wang, Z., Qiang, W., Ke, H.A., 2020, *A Handbook of 2019-nCoV Pneumonia Control and Prevention*, Hubei Science and Technologi Press, China.
- Weitz, J.I., Eikelboom, J.W., Samama, M.M., 2012, New Antithrombotic Drugs. *Chest* 141, e120S–e151S, <https://doi.org/10.1378/chest.11-2294>.
- Wells, B.G., Joseph, T.D., Terry, L.S., Cecily, V.D., 2015, *Pharmacotherapy Handbook*, 9th ed, McGraw-Hill Education/Medical, New York.
- WHO, 2016, *WHO|Women's health*, <http://www.who.int/mediacentre/factsheets/fs334/en/>, 14 November 2021.
- WHO, 2020a, WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020, <https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020>, 14 November 2021.
- WHO, 2020b, Clinical management of severe acute respiratory infection when

novel coronavirus (nCoV) infection is suspected, <https://www.who.int/publications-detail-redirect/10665-332299>, 14 November 2021.

- Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A.S., Burdelski, C., de Heer, G., Nierhaus, A., Frings, D., Pfefferle, S., Becker, H., Bredereke-Wiedling, H., de Weerth, A., Paschen, H.-R., Sheikhzadeh-Eggers, S., Stang, A., Schmiedel, S., Bokemeyer, C., Addo, M.M., Aepfelbacher, M., Püschel, K., Kluge, S., 2020, Autopsy Findings and Venous Thromboembolism in Patients With COVID-19, *Annals of International Medicine* 173, 268-277, <https://doi.org/10.7326/M20-2003>.
- Widjaja, J.T., Limdawati, K., Andreas, K.G., Henry, A.S., Christian, E., Ranietha, L.P., 2021, Karakteristik Pasien Covid-19 Rawat Inap di RS Immanuel Bandung Indonesia, *Journal of Medicine and Health* 3, 164-175, <https://doi.org/10.28932/jmh.v3i2.3781>.
- Yao, Y., Jiatian, C., Qingping, W., Qingfeng, S., Kai, L., Zhe, L., Xiang, C., Sisi, C., Kaihuan, Y., Zheyong, H., bijie, H., 2020, D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study, *Journal of Intensive Care* 8, 49, <https://doi.org/10.1186/s40560-020-00466-z>.
- Ye, G., Pan, Z., Pan, Y., Deng, Q., Chen, L., Li, J., Li, Y., Wang, X., 2020, Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation, *The Journal of Infection* 80, e14–e17, <https://doi.org/10.1016/j.jinf.2020.03.001>.
- Yu, H. H., Qin, C., Chen, M., Wang, W., Tian, D.S., 2020, D-dimer level is associated with the severity of COVID-19, *Thrombosis Research* 195, 219–225, <https://doi.org/10.1016/j.thromres.2020.07.047>.
- Zhang, S., Li, Y., Liu, G., Su, B., 2021, Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis, *Thrombosis J* 19, 91, <https://doi.org/10.1186/s12959-021-00343-1>.
- Zhu, X.T., Chen, L., Lin, J.H., 2018, Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis, *Medicine* 97, e11649, <https://doi.org/10.1097/MD.00000000000011649>.
- Zhu, J., Ji, P., Pang, J., Zhong, Z., Li, H., He, C., Zhang, J., Zhao, C., 2020, Clinical Characteristics Of 3062 COVID-19 Patients: A Meta-Analysis. *J Med Virol* 92, 1902-1914, <https://doi.org/10.1002/jmv.25884>.
- Zulfadli, N.K. A., Ahmad, Z., Saleh, M.I., Rasyid, A., 2021, The correlation between absolute lymphocyte count and quantitative CRP level related to disease severity in COVID-19 patients at RSUP dr. Mohammad Hoesin Palembang, *Sriwijaya Journal of Medicine* 4, 107-116, <https://doi.org/10.32539/SJM.v4i2.523>.